{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:28:54Z","timestamp":1790116134222,"version":"4.0.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod Biol Endocrinol"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Previous studies have reported conflicting results for the comparative doses of recombinant follicle stimulating hormone (rFSH) and highly purified human menopausal gonadotrophin (hMG-HP) required per cycle of <jats:italic>in vitro<\/jats:italic> fertilisation (IVF); the aim of this study was to determine the average total usage of rFSH versus hMG-HP in a 'real-world' setting using routine clinical practice.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This retrospective chart review of databases from four European countries investigated gonadotrophin usage, oocyte and embryo yield, and pregnancy outcomes in IVF cycles (\u00b1 intra-cytoplasmic sperm injection) using rFSH or hMG-HP alone. Included patients met the National Institute for Health and Clinical Excellence (NICE) guideline criteria for IVF and received either rFSH or hMG-HP. Statistical tests were conducted at 5% significance using Chi-square or t-tests.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of 30,630 IVF cycles included in this review, 74% used rFSH and 26% used hMG-HP. A significantly lower drug usage per cycle for rFSH than hMG-HP (2072.53 +\/- 76.73 IU vs. 2540.14 +\/- 883.08 IU, 22.6% higher for hMG-HP; p &lt; 0.01) was demonstrated. The median starting dose was also significantly lower for rFSH than for hMG-HP (150 IU vs. 225 IU, 50% higher for hMG-HP, p &lt; 0.01). The average oocyte yield per IVF cycle in patients treated with rFSH was significantly greater than with hMG-HP (10.80 +\/- 6.02 vs. 9.77 +\/- 5.53; p &lt; 0.01), as was the average mature oocyte yield (8.58 +\/- 5.27 vs. 7.72 +\/- 4.59; p &lt; 0.01). No significant differences were observed in pregnancy outcomes including spontaneous abortion between the two treatments. There was a significantly higher rate of OHSS (all grades) with rFSH (18.92% vs. 14.09%; p &lt; 0.0001). The hospitalisation rate due to OHSS was low but significantly higher in the rFSH group (1.07% of cycles started vs. 0.67% of cycles started with rFSH and hMG-HP, respectively; p = 0.002).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Based on these results, IVF treatment cycles with rFSH yield statistically more oocytes (and more mature oocytes), using significantly less IU per cycle, versus hMG-HP. The incidence of all OHSS and hospitalisations due to OHSS was significantly higher in the rFSH cycles compared to the hMG-HP cycles. However, the absolute incidence of hospitalisations due to OHSS was similar to that reported previously. These results suggest that the perceived required dosage with rFSH is currently over-estimated, and the higher unit cost of rFSH may be offset by a lower required dosage compared with hMG-HP.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1477-7827-8-137","type":"journal-article","created":{"date-parts":[[2010,11,12]],"date-time":"2010-11-12T15:50:51Z","timestamp":1289577051000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["In vitro fertilisation with recombinant follicle stimulating hormone requires less IU usage compared with highly purified human menopausal gonadotrophin: results from a European retrospective observational chart review"],"prefix":"10.1186","volume":"8","author":[{"given":"Geoffrey H","family":"Trew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam P","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Gillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Blackmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Clewlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"O'Donohoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radoslaw","family":"Wasiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,11,8]]},"reference":[{"issue":"6","key":"761_CR1","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/humrep\/dem035","volume":"22","author":"CH Ramlau-Hansen","year":"2007","unstructured":"Ramlau-Hansen CH, Thulstrup AM, Nohr EA, Bonde JP, Sorensen TI, Olsen J: Subfecundity in overweight and obese couples. Hum Reprod. 2007, 22 (6): 1634-1637. 10.1093\/humrep\/dem035.","journal-title":"Hum Reprod"},{"issue":"2","key":"761_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1365-2605.2007.00827.x","volume":"31","author":"TK Jensen","year":"2008","unstructured":"Jensen TK, Sobotka T, Hansen MA, Pedersen AT, Lutz W, Skakkebaek NE: Declining trends in conception rates in recent birth cohorts of native Danish women: a possible role of deteriorating male reproductive health. Int J Androl. 2008, 31 (2): 81-92. 10.1111\/j.1365-2605.2007.00827.x.","journal-title":"Int J Androl"},{"issue":"7","key":"761_CR3","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1093\/humrep\/16.7.1518","volume":"16","author":"The ESHRE Capri Workshop Group","year":"2001","unstructured":"The ESHRE Capri Workshop Group: Social determinants of human reproduction. Hum Reprod. 2001, 16 (7): 1518-1526. 10.1093\/humrep\/16.7.1518.","journal-title":"Hum Reprod"},{"issue":"6","key":"761_CR4","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1093\/humrep\/dem046","volume":"22","author":"J Boivin","year":"2007","unstructured":"Boivin J, Bunting L, Collins JA, Nygren KG: International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum Reprod. 2007, 22 (6): 1506-1512. 10.1093\/humrep\/dem046.","journal-title":"Hum Reprod"},{"key":"761_CR5","volume-title":"Fertility Facts and Figures 2007","author":"HFEA","year":"2009","unstructured":"HFEA: Fertility Facts and Figures 2007. 2009, [http:\/\/www.hfea.gov.uk\/docs\/adbcdfh.pdf]"},{"key":"761_CR6","volume-title":"Human menopausal gonadotropin and recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles","author":"LG Westergaard","year":"2003","unstructured":"Westergaard LG, Bossuyt PM, van der Veen F, van Wely M: Human menopausal gonadotropin and recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database of Systematic Reviews. 2003, [http:\/\/onlinelibrary.wiley.com\/o\/cochrane\/clsysrev\/articles\/CD003973\/frame.html]1"},{"issue":"12","key":"761_CR7","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1093\/humrep\/del284","volume":"21","author":"AN Andersen","year":"2006","unstructured":"Andersen AN, Devroey P, Arce JC: Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Hum Reprod. 2006, 21 (12): 3217-3227. 10.1093\/humrep\/del284.","journal-title":"Hum Reprod"},{"issue":"1","key":"761_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S1472-6483(10)60559-7","volume":"16","author":"HG Al-Inany","year":"2008","unstructured":"Al-Inany HG, Abou-Setta AM, Aboulghar MA, Mansour RT, Serour GI: Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: a meta-analysis. Reprod Biomed Online. 2008, 16 (1): 81-88. 10.1016\/S1472-6483(10)60559-7.","journal-title":"Reprod Biomed Online"},{"issue":"2","key":"761_CR9","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1093\/humrep\/dem305","volume":"23","author":"A Coomarasamy","year":"2008","unstructured":"Coomarasamy A, Afnan M, Cheema D, van der Veen F, Bossuyt PM, van Wely M: Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum Reprod. 2008, 23 (2): 310-315. 10.1093\/humrep\/dem305.","journal-title":"Hum Reprod"},{"issue":"6","key":"761_CR10","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1080\/09513590802630120","volume":"25","author":"HG Al-Inany","year":"2009","unstructured":"Al-Inany HG, Abou-Setta AM, Aboulghar MA, Mansour RT, Serour GI: Highly purified hMG achieves better pregnancy rates in IVF cycles but not ICSI cycles compared with recombinant FSH: a meta-analysis. Gynecol Endocrinol. 2009, 25 (6): 372-378. 10.1080\/09513590802630120.","journal-title":"Gynecol Endocrinol"},{"issue":"4","key":"761_CR11","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.fertnstert.2008.01.034","volume":"91","author":"J Wechowski","year":"2009","unstructured":"Wechowski J, Connolly M, Schneider D, McEwan P, Kennedy R: Cost-saving treatment strategies in in vitro fertilization: a combined economic evaluation of two large randomized clinical trials comparing highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone alpha. Fertil Steril. 2009, 91 (4): 1067-1076. 10.1016\/j.fertnstert.2008.01.034.","journal-title":"Fertil Steril"},{"issue":"5","key":"761_CR12","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/S0015-0282(03)02185-X","volume":"80","author":"A Lloyd","year":"2003","unstructured":"Lloyd A, Kennedy R, Hutchinson J, Sawyer W: Economic evaluation of highly purified menotropin compared with recombinant follicle-stimulating hormone in assisted reproduction. Fertil Steril. 2003, 80 (5): 1108-1113. 10.1016\/S0015-0282(03)02185-X.","journal-title":"Fertil Steril"},{"key":"761_CR13","volume-title":"Clinical Guideline 11: Assessment and treatment for people with fertility problems Understanding NICE guidance - information for people with fertility problems, their partners, and the public","author":"NICE","year":"2004","unstructured":"NICE: Clinical Guideline 11: Assessment and treatment for people with fertility problems Understanding NICE guidance - information for people with fertility problems, their partners, and the public. 2004, [http:\/\/www.nice.org.uk\/nicemedia\/pdf\/CG011publicinfoenglish.pdf]"},{"issue":"5","key":"761_CR14","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1016\/j.fertnstert.2009.09.009","volume":"92","author":"F Zegers-Hochschild","year":"2009","unstructured":"Zegers-Hochschild F, Adamson GD, de Mouzon J, Ishihara O, Mansour R, Nygren K, Sullivan E, Vanderpoel S: International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised glossary of ART terminology, 2009. Fertil Steril. 2009, 92 (5): 1520-1524. 10.1016\/j.fertnstert.2009.09.009.","journal-title":"Fertil Steril"},{"issue":"6","key":"761_CR15","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1093\/humrep\/dem049","volume":"22","author":"GH Trew","year":"2007","unstructured":"Trew GH: Comparing highly purified hMG and rFSH in patients undergoing IVF. Hum Reprod. 2007, 22 (6): 1797-1798. 10.1093\/humrep\/dem049. author reply 1798-1800","journal-title":"Hum Reprod"},{"key":"761_CR16","volume-title":"Multiple births and single embryo transfer review","author":"HFEA","year":"2010","unstructured":"HFEA: Multiple births and single embryo transfer review. 2010, [http:\/\/www.hfea.gov.uk\/530.html]"},{"key":"761_CR17","volume-title":"Ovarian hyperstimulation syndrome (OHSS): a short report for the HFEA","author":"A Balen","year":"2008","unstructured":"Balen A: Ovarian hyperstimulation syndrome (OHSS): a short report for the HFEA. 2008, [http:\/\/www.hfea.gov.uk\/docs\/OHSS_UPDATED_Report_from_Adam_Balen_2008.pdf]"},{"issue":"2","key":"761_CR18","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/humrep\/14.2.354","volume":"14","author":"M Ludwig","year":"1999","unstructured":"Ludwig M, Finas DF, al-Hasani S, Diedrich K, Ortmann O: Oocyte quality and treatment outcome in intracytoplasmic sperm injection cycles of polycystic ovarian syndrome patients. Hum Reprod. 1999, 14 (2): 354-358. 10.1093\/humrep\/14.2.354.","journal-title":"Hum Reprod"},{"issue":"2","key":"761_CR19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/oxfordjournals.humrep.a138029","volume":"8","author":"MJ MacDougall","year":"1993","unstructured":"MacDougall MJ, Tan SL, Balen A, Jacobs HS: A controlled study comparing patients with and without polycystic ovaries undergoing in-vitro fertilization. Hum Reprod. 1993, 8 (2): 233-237.","journal-title":"Hum Reprod"},{"issue":"1","key":"761_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.sapharm.2005.12.001","volume":"2","author":"FS Lobo","year":"2006","unstructured":"Lobo FS, Wagner S, Gross CR, Schommer JC: Addressing the issue of channeling bias in observational studies with propensity scores analysis. Res Social Adm Pharm. 2006, 2 (1): 143-151.","journal-title":"Res Social Adm Pharm"},{"key":"761_CR21","volume-title":"Annual Report: Schweizerische Gesellschaft f\u00fcr Reproduktionsmedizin Soci\u00e9t\u00e9 Suisse de M\u00e9decine de la Reproduction","author":"FIVNAT-CH","year":"2009","unstructured":"FIVNAT-CH: Annual Report: Schweizerische Gesellschaft f\u00fcr Reproduktionsmedizin Soci\u00e9t\u00e9 Suisse de M\u00e9decine de la Reproduction. 2009"}],"container-title":["Reproductive Biology and Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1477-7827-8-137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T04:42:59Z","timestamp":1630471379000},"score":1,"resource":{"primary":{"URL":"https:\/\/rbej.biomedcentral.com\/articles\/10.1186\/1477-7827-8-137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,8]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["761"],"URL":"https:\/\/doi.org\/10.1186\/1477-7827-8-137","relation":{},"ISSN":["1477-7827"],"issn-type":[{"value":"1477-7827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,8]]},"assertion":[{"value":"24 June 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"137"}}